Biotech IV Monitor

PTCT — PTC Therapeutics Inc.

$6.4B market cap · 4 upcoming readouts tracked

Clinical trial readout dates for PTC Therapeutics Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is September 2027.

Next readoutSeptember 2027in ~10 months
Upcoming readouts43 Phase 3
Market cap$6.4B
Cash & investments$2.09Bas of Sep 30, 2026
Recent 8-K filings2latest 2026-11-03

Upcoming readouts

Phase 2 PTC844
Rheumatoid Arthritis · NCT07779616
September 2027
Recruiting
Phase 3 Vatiquinone
Friedreich Ataxia · NCT05515536
December 2027
Ongoing
Phase 3 Vatiquinone
Friedreich's Ataxia · NCT07681713
March 2029
Not Yet Recruiting
Phase 3 Sepiapterin
Phenylketonuria · NCT06302348
February 2031
Recruiting

Cash position

PTC Therapeutics Inc. reported $2.09B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-10-29). Its net loss for that quarter was $52M.

Recent SEC filings

8-K Other Events — often topline trial data2026-11-03
8-K Reg FD Disclosure — often a data announcement2026-10-29

Companies working on similar indications

Discussion

No messages yet. If you follow PTCT, you can start the conversation.
Track PTCT in real time
See live implied volatility for PTCT and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on PTCT
Contact — questions or corrections about PTCT: dukeupt@gmail.com